Supernus Pharma Stock Price, News & Analysis

Supernus Pharmaceuticals (SUPN) is expanding its partnership with TV personality Jay Glazer and his wife Rosie in a new content series about ADHD and relationships. The four-part video series, launching on the All About ADHD YouTube channel in May 2025, explores how Qelbree (viloxazine extended-release capsules), a non-stimulant ADHD treatment, has helped Jay manage his symptoms. The series aims to provide insights into the challenges and successes of couples affected by ADHD, with Jay sharing his experience using Qelbree and Rosie discussing her supporting role. The first episode, "Jay & Rosie Glazer's ADHD Story: Real Life, Real Change," is now available. Qelbree is approved for ADHD treatment in adults and children 6 years and older, with important safety information including potential increased risk of suicidal thoughts and actions.

Supernus Pharmaceuticals (NASDAQ: SUPN), a biopharmaceutical company specializing in central nervous system (CNS) diseases, announced its participation in the 2025 Jefferies Global Healthcare Conference. President and CEO Jack A. Khattar will engage in a fireside chat on June 4, 2025, at 2:00 p.m. ET in New York City.

Investors can arrange meetings with management through the Jefferies conference coordinator. The presentation will be available via live audio webcast, accessible through the company's website, with a replay available for 60 days post-conference.

Supernus Pharmaceuticals (SUPN) has received Paragraph IV Notice Letters regarding Abbreviated New Drug Applications (ANDAs) from third parties for its drug Qelbree (viloxazine extended-release capsules) in 100, 150, and 200 mg base formulations. The company plans to vigorously defend its intellectual property rights for Qelbree, which is protected by six U.S. patents listed in the FDA's Orange Book. Three patents expire in September 2029, two in February 2033, and one in April 2035.

Supernus Pharmaceuticals (SUPN) has launched 'Ms. Represented,' a groundbreaking campaign featuring actress Busy Philipps to raise awareness about ADHD in women. The campaign highlights how females often present different ADHD symptoms than males, focusing on inattentive symptoms rather than hyperactivity. Due to this difference, boys are twice as likely to be diagnosed with ADHD than girls, leaving many women undiagnosed or untreated.

The campaign promotes Qelbree®, Supernus's once-daily non-stimulant ADHD treatment for patients 6 years and older. As the first non-stimulant approved for adults with ADHD in 20 years, Qelbree has no evidence of abuse potential and offers convenient prescription refills. The initiative, launched during Mental Health Awareness Month on Bustle, aims to empower women to recognize their ADHD symptoms and seek proper medical attention.

Supernus Pharmaceuticals (SUPN) reported mixed Q1 2025 financial results with total revenues increasing 4% to $149.8 million. Key highlights include Qelbree sales growing 44% to $64.7 million and GOCOVRI sales rising 16% to $30.7 million. However, the company posted an operating loss of $(10.3) million compared to $(3.2) million in 2024. The company launched ONAPGO for Parkinson's disease in April 2025. Qelbree showed strong prescription growth with 214,908 total prescriptions, up 22% YoY. The pipeline includes ongoing trials for SPN-817 (epilepsy), SPN-820 (depression), and SPN-443 (ADHD/CNS). Supernus maintains its 2025 guidance with total revenues of $600-$630 million and adjusted operating earnings of $105-$130 million.

Supernus Pharmaceuticals (SUPN) has scheduled its first quarter 2025 financial results announcement for Tuesday, May 6, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET on the same day, featuring President and CEO Jack Khattar and Senior VP and CFO Tim Dec.

The presentation will include Q1 2025 financial and business results, followed by a Q&A session. Investors can access the live webcast through the Events & Presentations section of Supernus' Investor Relations website. Pre-registration is available for participants, who will receive a personalized conference code. A replay will be available on the company's website for 60 days following the live call.

Supernus Pharmaceuticals (Nasdaq: SUPN), a biopharmaceutical company specializing in central nervous system (CNS) diseases, has announced its participation in upcoming March investor conferences. Jack Khattar, President and CEO, will represent the company at these events.

The company will feature a fireside chat at the Barclays Global Healthcare Conference, which will be available via live audio webcast. Investors can access the webcast through the Events & Presentations section of Supernus's website at www.supernus.com. The webcast recording will remain accessible for 60 days following the conference.

Interested investors seeking meetings with Supernus management during these conferences should reach out to the respective conference coordinators for arrangements.

Supernus Pharmaceuticals (Nasdaq: SUPN), a biopharmaceutical company specializing in central nervous system (CNS) diseases, has announced its participation in the TD Cowen 45th Annual Health Care Conference.

President and CEO Jack A. Khattar will engage in a fireside chat on March 3, 2025, at 11:10 a.m. ET in Boston, Mass. Interested investors can arrange meetings with management through the conference coordinator.

The presentation will be accessible via live audio webcast through the company's website investor relations section, with a replay available for 60 days post-conference.

Supernus Pharmaceuticals (SUPN) reported strong financial results for Q4 and full year 2024, with total revenues increasing 9% to $661.8 million. Qelbree showed exceptional growth with Q4 net sales up 60% to $74.4 million and full-year sales up 72% to $241.3 million. GOCOVRI sales also improved, rising 15% in Q4 to $36.9 million.

The company achieved full-year 2024 operating earnings of $81.7 million, compared to a loss in 2023. Notable developments include FDA approval of ONAPGO for Parkinson's disease, planned for launch in Q2 2025, and a patent extension for Qelbree until 2035.

For 2025, Supernus projects total revenues between $600-630 million and adjusted operating earnings of $105-130 million. The company maintains a strong financial position with $453.6 million in cash and marketable securities as of December 31, 2024.